Other Events ·
Oruka reports 61% PASI 100 with ORKA-001 in Phase 2b psoriasis trial
ORKAOruka Therapeutics, Inc.
Oruka Therapeutics announced Week 16 results from its Phase 2b EVERLAST-B clinical trial of ORKA-001, an investigational IL-23p19 monoclonal antibody, in patients with moderate-to-severe plaque psoriasis. In the high-dose (600 mg) group, 61% of patients achieved PASI 100 at Week 16 compared to 0% for placebo (p<0.0001). Additionally, 86% of high-dose patients achieved PASI 90 and IGA 0/1. The drug demonstrated a favorable safety profile with no serious treatment-emergent adverse events in the high-dose group. Oruka plans to initiate Phase 3 trials for ORKA-001 in the first half of 2027, pending regulatory discussions. The company also reported a cash position of $1.1 billion as of June 30, 2026. Oruka Therapeutics is a clinical-stage biotechnology company developing novel biologics for chronic skin diseases including plaque psoriasis and hidradenitis suppurativa.